Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: A 12-week randomized, double-blind, placebo-controlled trial

Menopause

Volumn 13, Issue 5, 2006, Pages 744-759

  Heger, Marianne ^a   Ventskovskiy, Boris M ^b   Borzenko, Irina ^c   Kneis, Kyra C ^a   Rettenberger, Reinhard ^d   Kaszkin Bettag, Marietta ^a   Heger, Peter W ^a  

^a Health Research Services Ltd   (Germany)

^b BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^c Health Research Services Ltd   (Ukraine)

^d Chemisch Pharmazeutische Fabrik Goeppingen   (Germany)

Author keywords

Climacteric complaints; Clinical trial; Herbal drug; Menopause; Menopause rating scale; Menopause specific Quality of Life Questionnaire

Indexed keywords

DESOXYRHAPONTICIN; DESOXYRHAPONTIGENIN; ERR 731; PLACEBO; PLANT MEDICINAL PRODUCT; RESVERATROL; RHAPONTIGENIN; RHAPONTIN; RHEUM RHAPONTICUM EXTRACT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; BREAST TENDERNESS; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ENTERIC COATED TABLET; FEMALE; HOT FLUSH; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE RATING SCALE II; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PROSPECTIVE STUDY; PULSE RATE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHUBARB; SCORING SYSTEM; SYMPTOM;

BODY MASS INDEX; CLIMACTERIC; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; PERIMENOPAUSE; PHYTOTHERAPY; PLANT PREPARATIONS; PLANT ROOTS; QUALITY OF LIFE; RHEUM; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 33748926108     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000240632.08182.e4     Document Type: Article

References (49)

1. Boulet MJ, Oddens BJ, Lebert P, et al. Climacteric in menopause in seven south-east Asian countries. Metabolism 1994;80:1685-1690.
2. Johannes, et al. Menstrual bleeding, hormones and the menopausal transition. Seminars in reproductive endocrinology 1999;17.
3. Dudley EC, Hopper JL, Tappe J, et al. Using longitudinal data to define the perimenopause by menstrual cycle characteristics. Climacteric 1998;1:18-25.
4. Lindsay R, Thome F. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:291-295.
5. Skafar DF, Xu R, Morales J, et al. Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 1997;82:3913-3918.
6. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51+epidemiological studies of 52,705 women without breast cancer. Lancet 1997;359:1047-1059.
8. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
9. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-344.
10. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in health postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.
12. Chlebowski RT, Hendrix SL, Langer RD, et al, for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253.
13. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
14. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female Hormones and Thrombosis. Arterioscler Thromb Vasc Biol 2002;22:201-210.
15. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
16. Beck V, Unterrieder E, Krenn W, et al. Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Ster Biochem Mol Biol 2003;84:259-268.
17. Krebs EE, Ensrud KE, MacDonald R, Wild TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824-836.
18. Naftolin F, Stanbury MG. Phytoestrogens: are they really estrogen mimics? Fertil Steril 2002;77:15-17.
19. Russsell L, Hicks GS, Low AK, et al. Phytoestrogens: a viable option? Am J Med Sci 2002;324:185-188.
20. Mueller SO, Simon S, Chae K, et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ER-α) and ER-β in human cells. Toxicol Sci 2004;80:14-25.
21. Verhoeven MO, van der Mooren MJ, van de Weijer PH, et al. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause 2005;12:412-420.
22. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-2840.
23. Usui T, Ikeda Y, Tagami T, et al. The phytochemical lindleyin, isolated from Rhei rhizome, mediates hormonal effects through estrogen receptors. J Endocrinol 2002;175:289-296.
24. Matsuda H, Shimoda H, Morikawa T, Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorg Med Chem Lett 2001;11:1839-1842.
25. Hauser GA, Schneider HPG, Rosemeier PJ, et al. Die Selbstbeurteilungs- Skala für klimakterische Beschwerden (Menopause Rating Scale II). J Menopause 1999;4:13-17.
26. Potthoff P, Heinemann LA, Schneider HP, Rosemeier HP, Hauser GA. The Menopause Rating Scale (MRS II): methodological standardization in the German population. Zentralbl Gynakol 2000;122:280-286.
27. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999;55:1286-1290.
28. Wassmer G. Statistical Test Methods for Group Sequential and Adaptive Designs in Clinical Studies. Theoretical Foundations and Practical Implementations using SAS. Cologne, Germany: Verlag Alexander Mönch, 1999.
29. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
30. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175.
31. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the menopause-specific quality of life questionnaire and development of a modified version, MENQOL-intervention questionnaire. Maturitas 2005;50:209-221.
32. Rowe T. Hormone replacement therapy: what is available now, and what is on the horizon. Product monograph Activelle. Novo Nordisk 2003. BC Medical Journal 2001;43:521-526.
33. Product Monograph Activelle, Novo Nordisk Pharma GmbH, Mainz Germany, 1999.
34. Altshuler LL, Cohen LS, Moline ML, et al. Treatment of depression in women: a summary of the expert consensus guidelines. J Psychiatr Pract 2001;7:185-208.
35. Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr Womens Health Rep 2002;2:182-187.
36. EMEA, Recommendation on the need for revision of the CPMP points to consider on hormone replacement therapy. CHMP/EWP/021/097, Rev. 1, 2005.
37. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105:1063-1073.
38. EMEA, Committee for proprietary medicinal products (CPMP), points to consider on hormone replacement therapy, CPMP/EWP/021/97 1997.
39. Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA. Reflections on the discovery and significance of estrogen receptor β. Endocrine Rev 2005;26:465-478.
40. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ER-α and ER-β, in estrogen target tissues in vivo through the use of an ER-α-selective ligand. Endocrinology 2002;143:4172-4177.
41. Krezel W, Dupont S, Krust A, et al. Increased anxiety and synaptic plasticity in estrogen receptor β-deficient mice. Proc Natl Acad Sci U S A 2001;98:12278-12282.
42. Lund TD, Rovis T, Chung WCJ, Handa RJ. Novel actions of estrogen receptor β on anxiety-related behaviours. Endocrinology 2005;146:797-807.
43. Walf AA, Rhodes ME, Frye CA. Antidepressant effects of ER-β-selective estrogen receptor modulators in the forced swim test. Pharmacol Biochem Behav 2004;78:523-529.
44. Walf AA, Frye CA. ER-β-selective estrogen receptor modulators produce antianxiety behaviour when administered systemically to ovariectomized rats. Neuropsychopharmacology 2005:1-12.
45. Imwalle DB, Gustafsson JA, Rissman EF. Lack of functional estrogen receptor β influences anxiety behavior and serotonin content in female mice. Physiol Behav 2005;84:157-163.
46. Hewitt SC, Couse JF, Korach KS. Estrogen receptor transcription and transactivation estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res 2000;2:345-352.
47. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005;67:285-308.
48. Frasor J, Barnett DH, Danes JM, et al. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER)-α activity by ERβ in the uterus. Endocrinology 2003;144:3159-3166.
49. Lindberg MK, Moverare S, Skrtic S, et al. Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a "ying yang" relationship between ERα and ERβ in mice. Mol Endocrinol 2003;17:203-208.